The results showed that, compared with valsartan, ARNI reduced the risk of the primary endpoint by 13%, although it did not reach statistical significance ( P = 0.059).
← all excerpts
Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides.
1
0.0590
0.0590